Evidence map›Paper›PMID 36109736›Full record

ArticleMicrobial cell factories2022

Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CB

Miquel Saumell-Esnaola, Ainhoa Elejaga-Jimeno, Leyre Echeazarra, Leire Borrega-Román, Sergio Barrondo, Maider López de Jesús, Imanol González-Burguera, Alberto Gómez-Caballero, María Aranzazu Goicolea, Joan Sallés and 1 more

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Miquel Saumell-EsnaolaDepartment of Pharmacology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.
Ainhoa Elejaga-JimenoDepartment of Analytical Chemistry, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.
Leyre EcheazarraDepartment of Physiology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.
Leire Borrega-RománDepartment of Pharmacology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.
Sergio BarrondoDepartment of Pharmacology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.
Maider López de JesúsDepartment of Pharmacology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.
Imanol González-BurgueraBioaraba, Neurofarmacología Celular y Molecular, 01008, Vitoria-Gasteiz, Spain.
Alberto Gómez-CaballeroDepartment of Analytical Chemistry, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.
María Aranzazu GoicoleaDepartment of Analytical Chemistry, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.
Joan SallésDepartment of Pharmacology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.
Gontzal García Del CañoBioaraba, Neurofarmacología Celular y Molecular, 01008, Vitoria-Gasteiz, Spain. gontzal.garcia@ehu.eus.
University of the Basque Country · ESCentro de Investigación Biomédica en Red de Salud Mental · ES

Funding

Basque Government (Research Groups of the Basque University System) IT1492-22Basque Government (Research Groups of the Basque University System) IT1620-22Spanish Ministry of Science, Innovation and Universities CTQ2017-85686-R
6 · The paper itself

Abstract

backgroundReplacement of radioligand binding assays with antibody-antigen interaction-based approaches for quantitative analysis of G protein-coupled receptor (GPCR) levels requires the use of purified protein standards containing the antigen. GPCRs in general and cannabinoid CB

resultsHere we generated highly soluble and stable recombinant protein constructs GST-CB1

conclusionsCollectively, here we provide a suitable Western blot-based design as a simple, cost-effective and radioactivity-free alternative for the quantitative analysis of CB

Indexed as

Blotting, WesternReceptors, CannabinoidAnimalsCell MembraneHumansMiceRatsRecombinant ProteinsReceptors, CannabinoidRecombinant ProteinsCannabinoid CB1 receptor antibodiesCarboxy-terminal tailGPCR expression analysisGST fusion proteinsQuantitative Western blotRadioligand saturation bindingSoluble recombinant protein standards

Identifiers

PMID36109736
PMCPMC9479267
OpenAlexW4296038314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.